The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
Open accessAbstract
In recent years, prominent roles for microRNAs (miRNAs) have been uncovered in several cardiovascular disorders. The ability to therapeutically manipulate miRNA expression and function through systemic or local delivery of miRNA inhibitors, referred to as antimiRs, has triggered enthusiasm for miRNAs as novel therapeutic targets. Here, we focus on the pharmacokinetic and pharmacodynamic properties of current antimiR designs and their relevance to cardiovascular indications, and evaluate the opportunities and obstacles associated with this new therapeutic modality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
The Human Angiotensin II Type 1 Receptor +1166 A/C Polymorphism Attenuates MicroRNA-155 Binding
Martin, M. M., Buckenberger, J. A., Jiang, J., Malana, G. E., Nuovo, G. J., Chotani, M., Feldman, D. S., Schmittgen, T. D., & Elton, T. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701050200 · Cited by 259
RetractedMicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
Salmena, L., Poliseno, L., Tay, Y., Kats, L., & Pandolfi, P. P. (2011) · Cell · doi:10.1016/j.cell.2011.07.014 · Cited by 7,262
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Mammalian microRNAs predominantly act to decrease target mRNA levels
Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010) · Nature · doi:10.1038/nature09267 · Cited by 3,886
The impact of microRNAs on protein output
Baek, D., Villén, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. (2008) · Nature · doi:10.1038/nature07242 · Cited by 3,592
Widespread changes in protein synthesis induced by microRNAs
Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008) · Nature · doi:10.1038/nature07228 · Cited by 3,429
Transient Regenerative Potential of the Neonatal Mouse Heart
Porrello, E. R., Mahmoud, A. I., Simpson, E., Hill, J. A., Richardson, J. A., Olson, E. N., & Sadek, H. A. (2011) · Science · doi:10.1126/science.1200708 · Cited by 2,545
Self-citationMicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082
Cited by
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H., Fabbri, M., & Calin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,465
Therapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
The war against heart failure: the Lancet lecture
Braunwald, E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61889-4 · Cited by 811
Long Noncoding RNAs in Cardiovascular Diseases
Uchida, S., & Dimmeler, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.302521 · Cited by 739
Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy
Hinson, J. T., Chopra, A., Nafissi, N., Polacheck, W. J., Benson, C. C., Swist, S., Gorham, J., Yang, L., Schafer, S., Sheng, C. C., et al. (2015) · Science · doi:10.1126/science.aaa5458 · Cited by 638
MicroRNA Regulation of Atherosclerosis
Feinberg, M. W., & Moore, K. J. (2016) · Circulation Research · doi:10.1161/circresaha.115.306300 · Cited by 627
Development of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625
Self-citationHuynh, K., Bernardo, B. C., McMullen, J. R., & Ritchie, R. H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.003 · Cited by 553
Mitochondria and Endothelial Function
Kluge, M. A., Fetterman, J. L., & Vita, J. A. (2013) · Circulation Research · doi:10.1161/circresaha.111.300233 · Cited by 508
“There is recent appreciation of the importance of microRNAs (miRs) in the coordination of many biological processes.(212) In”
BackgroundTargeting vascular (endothelial) dysfunction
Daiber, A., Steven, S., Weber, A., Shuvaev, V. V., Muzykantov, V. R., Laher, I., Li, H., Lamas, S., & Münzel, T. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13517 · Cited by 501
MicroRNAs in Cardiovascular Disease
Barwari, T., Joshi, A., & Mayr, M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.945 · Cited by 445
Therapeutic approaches for cardiac regeneration and repair
Hashimoto, H., Olson, E. N., & Bassel-Duby, R. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0036-6 · Cited by 415
Self-citationLong Noncoding RNAs and MicroRNAs in Cardiovascular Pathophysiology
Thum, T., & Condorelli, G. (2015) · Circulation Research · doi:10.1161/circresaha.116.303549 · Cited by 385
microRNAs in Cardiovascular Diseases
Condorelli, G., Latronico, M. V. G., & Cavarretta, E. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.050 · Cited by 375
Adult-specific functions of animal microRNAs
Sun, K., & Lai, E. C. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3471 · Cited by 334
Molecular Mechanisms Underlying Cardiac Adaptation to Exercise
Vega, R. B., Konhilas, J. P., Kelly, D. P., & Leinwand, L. A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.025 · Cited by 307
MicroRNAs in Heart Failure: From Biomarker to Target for Therapy
Vegter, E. L., van der Meer, P., de Windt, L. J., Pinto, Y. M., & Voors, A. A. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.495 · Cited by 303
Baumann, V., & Winkler, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.116 · Cited by 297
Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling
Horn, M. A., & Trafford, A. W. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.11.005 · Cited by 275
Circular RNA vaccine in disease prevention and treatment
Niu, D., Wu, Y., & Lian, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01561-x · Cited by 267
A landscape of circular RNA expression in the human heart
Tan, W. L. W., Lim, B. T. S., Anene-Nzelu, C. G. O., Ackers-Johnson, M., Dashi, A., See, K., Tiang, Z., Lee, D. P., Chua, W. W., Luu, T. D. A., et al. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvw250 · Cited by 265
Akat, K. M., Moore-McGriff, D., Morozov, P., Brown, M., Gogakos, T., Correa Da Rosa, J., Mihailovic, A., Sauer, M., Ji, R., Ramarathnam, A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401724111 · Cited by 254
Karunakaran, D., Thrush, A. B., Nguyen, M.-A., Richards, L., Geoffrion, M., Singaravelu, R., Ramphos, E., Shangari, P., Ouimet, M., Pezacki, J. P., et al. (2015) · Circulation Research · doi:10.1161/circresaha.117.305624 · Cited by 188
A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis
Chioccioli, M., Roy, S., Newell, R., Pestano, L., Dickinson, B., Rigby, K., Herazo-Maya, J., Jenkins, G., Ian, S., Saini, G., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104304 · Cited by 129
Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators
Flierl, U., Nero, T. L., Lim, B., Arthur, J. F., Yao, Y., Jung, S. M., Gitz, E., Pollitt, A. Y., Zaldivia, M. T. K., Jandrot-Perrus, M., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140391 · Cited by 114
Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy
Deng, R., Shen, N., Yang, Y., Yu, H., Xu, S., Yang, Y.-W., Liu, S., Meguellati, K., & Yan, F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.013 · Cited by 106
Managing MicroRNAs with Vector-Encoded Decoy-Type Inhibitors
Bak, R. O., Hollensen, A. K., & Mikkelsen, J. G. (2013) · Molecular Therapy · doi:10.1038/mt.2013.113 · Cited by 49
Methods and novel technology for microRNA quantification in colorectal cancer screening
Moody, L., He, H., Pan, Y.-X., & Chen, H. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0420-9 · Cited by 42
Circulating Level of miR-378 Predicts Left Ventricular Hypertrophy in Patients with Aortic Stenosis
Chen, Z., Li, C., Xu, Y., Li, Y., Yang, H., & Rao, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105702 · Cited by 36
Jan, A., Karasinska, J. M., Kang, M. H., de Haan, W., Ruddle, P., Kaur, A., Connolly, C., Leavitt, B. R., Sorensen, P. H., & Hayden, M. R. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.05.007 · Cited by 28
Metadata
- Authors
- van Rooij, E., & Olson, E. N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-10-19
- Volume
- 11
- Issue
- 11
- Pages
- 860-872
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2072190764
- Cited by
- 624
- References
- 107
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.